Human β-Amyloid 1-42 Antibody (2C2G5), mAb, Mouse

USA

-20°C

GenScript Human β, -Amyloid 1-42 Antibody (2C2G5), mAb, Mouse detects human β, -Amyloid 1-42 and does not cross-react with human β, -Amyloid 1-40.

A number of mutations, identified in the gene encoding the beta-amyloid precursor protein (betaAPP), have been linked to early-onset Familial Alzheimers Disease. betaAPP is cleaved sequentially by the proteolytic enzymes beta-secretase and gamma-secretase to produce beta-amyloid (Abeta) peptides with the Abeta1-42(43) and the Abeta1-40 forms being the most prevalent. Secreted Abeta peptides can bind to scavenger receptors and the receptor for advanced glycation end products. Abeta peptides are degraded either via a reuptake mechanism followed by endosomal degradation or by an extracellular insulin-degrading enzyme. Extracellular accumulation of Abeta leads to formation of aggregates, fibrils, and eventually amyloid deposits called neuritic plaques, a hallmark of Alzheimer’s disease. beta-amyloid antibodies and peptides have been developed as tools for elucidating the biology of Alzheimers disease.GenScript Human beta-Amyloid 1-42 Antibody (2C2G5), mAb, Mouse is produced from the hybridoma resulting from fusion of Sp2/0 myeloma and B-lymphocytes obtained from mouse immunized with a synthetic peptide corresponding to amino acids 36-42 of human beta-Amyloid conjugated to KLH (Swiss Prot: P05067).

Reconstitute 40 ug lyophilized powder with 80 ul of deionized water (or equivalent) to antibody concentration of 0.5 mg/ml.